



# Cerur Endovascular

May 2, 2023,

Dear Shareholders,

On behalf of myself and the (now former) Board of Directors, I am pleased to report that we have, at last, closed the acquisition of Cerur Endovascular Ltd. by Stryker Corp.

As you all know the many hurdles that we had to overcome – especially in the early days – none of this would have happened without the tireless, creative efforts of our extraordinarily gifted team led by Stephen Griffin. We cannot thank them enough, but I wanted you to know their names and articulate our gratitude and respect for all their efforts.

As you know this is a structured deal with three remaining milestones to complete and to that end, Stephen and virtually the entire the Cerur team will continue within the Stryker organization going forward.

Below are the names and titles of the Cerur team that made this happen:

Stephen	Griffin	Chief Executive Officer
David	Jennings	Chief Financial Officer
Alex	Bremner	VP Commercial - EMEA
Jeff	Sarge	Vice President R&D
Nick	Murtagh	Therapy Development Manager
Sergei	Garcia Lopez	Marketing Director - Europe
Alberto	Encino Lopez	Senior Business Development Manager
Andy	Nguyen	Senior R&D Technician
Perry	Fukui	Vice President Quality & Operations
Kevin	Wong	Senior Quality Engineer
Lori	Adels	Chief Compliance Officer
Ryan	Woo	Senior Quality Engineer
Sarge	Vanessa	Clinical Research Associate
Carin	Lindquist	Director of Clinical Operations
Anne	Lokke	Senior Manager Regulatory Affairs
Giovanni	Cordiglia	Quality Control Technician
Chris	Gahm	Field Clinical Trials Manager
Michelle	Lewman	Accounts & Office manager

I would also add that without your funding, patience and support we would never have achieved this goal.



Cerus  
Endovascular

It has been an honor for me to be at Cerus, to work with the Board – Paul Brooke, Franklin Berger and John Kilcoyne – and to get to know the shareholders and of course the Cerus team.

I hope our paths will cross again.

Best,

Sam Milstein